A history of stroke/transient ischemic attack indicates high risks of cardiovascular event and hemorrhagic stroke in patients with coronary artery disease

Gregory Ducrocq, Pierre Amarenco, Julien Labreuche, Mark J. Alberts, Jean Louis Mas, E. Magnus Ohman, Shinya Goto, Philippa Lavallée, Deepak L. Bhatt, Ph Gabriel Steg

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Background-Randomized trials of antithrombotics in coronary artery disease have identified previous stroke/transient ischemic attack (TIA) as a marker of increased intracranial bleeding risk. We aimed to further characterize the risk of ischemic and bleeding events associated with a history of stroke/TIA in patients with coronary artery disease. Methods and Results-From the international REduction of Atherothrombosis for Continued Health (REACH) registry of atherothrombosis, baseline characteristics and 4-year follow-up of 26 389 patients with coronary artery disease, including 4460 patients (16.9%) with a history of stroke/TIA, were analyzed. Patients with previous stroke/TIA had a higher rate of recurrent cardiovascular events (cardiovascular death, myocardial infarction, or stroke) than patients without (adjusted hazard ratio [HR], 1.52; 95% confidence interval [CI], 1.40-1.65; P<0.001) and specifically of nonfatal ischemic stroke (adjusted HR, 3.06; 95% CI, 2.62-3.57; P<0.001) and nonfatal hemorrhagic stroke rates (adjusted HR, 1.76; 95% CI, 1.00-3.08; P=0.05). Excess risk for nonfatal hemorrhagic stroke appeared confined to the 1st year after a stroke/TIA (adjusted HR, 3.03; 95% CI, 1.51-6.08 for the first year) and was particularly high in patients receiving dual antiplatelet therapy (adjusted HR, 5.21; 95% CI, 1.24-21.90). Conclusions-In patients with coronary artery disease, a history of stroke/TIA is associated with an independent increase in risk of death, myocardial infarction, or stroke, including both ischemic and hemorrhagic stroke (the latter being smaller in absolute terms). This excess risk of hemorrhagic stroke is particularly high in patients receiving dual antiplatelet therapy and in the 1st year after stroke/TIA. This observation is important for selection of antithrombotic therapy in these patients. (Circulation. 2013;127:730-738.).

Original languageEnglish (US)
Pages (from-to)730-738
Number of pages9
JournalCirculation
Volume127
Issue number6
DOIs
StatePublished - Feb 12 2013

Fingerprint

Transient Ischemic Attack
Coronary Artery Disease
Stroke
Confidence Intervals
Myocardial Infarction
Hemorrhage
Registries
Therapeutics

Keywords

  • Antiplatelet agents
  • Hemorrhage
  • Myocardial ischemia
  • Stroke

ASJC Scopus subject areas

  • Physiology (medical)
  • Cardiology and Cardiovascular Medicine

Cite this

A history of stroke/transient ischemic attack indicates high risks of cardiovascular event and hemorrhagic stroke in patients with coronary artery disease. / Ducrocq, Gregory; Amarenco, Pierre; Labreuche, Julien; Alberts, Mark J.; Mas, Jean Louis; Ohman, E. Magnus; Goto, Shinya; Lavallée, Philippa; Bhatt, Deepak L.; Steg, Ph Gabriel.

In: Circulation, Vol. 127, No. 6, 12.02.2013, p. 730-738.

Research output: Contribution to journalArticle

Ducrocq, Gregory ; Amarenco, Pierre ; Labreuche, Julien ; Alberts, Mark J. ; Mas, Jean Louis ; Ohman, E. Magnus ; Goto, Shinya ; Lavallée, Philippa ; Bhatt, Deepak L. ; Steg, Ph Gabriel. / A history of stroke/transient ischemic attack indicates high risks of cardiovascular event and hemorrhagic stroke in patients with coronary artery disease. In: Circulation. 2013 ; Vol. 127, No. 6. pp. 730-738.
@article{4813a1284a444691b584f67bccc4700c,
title = "A history of stroke/transient ischemic attack indicates high risks of cardiovascular event and hemorrhagic stroke in patients with coronary artery disease",
abstract = "Background-Randomized trials of antithrombotics in coronary artery disease have identified previous stroke/transient ischemic attack (TIA) as a marker of increased intracranial bleeding risk. We aimed to further characterize the risk of ischemic and bleeding events associated with a history of stroke/TIA in patients with coronary artery disease. Methods and Results-From the international REduction of Atherothrombosis for Continued Health (REACH) registry of atherothrombosis, baseline characteristics and 4-year follow-up of 26 389 patients with coronary artery disease, including 4460 patients (16.9{\%}) with a history of stroke/TIA, were analyzed. Patients with previous stroke/TIA had a higher rate of recurrent cardiovascular events (cardiovascular death, myocardial infarction, or stroke) than patients without (adjusted hazard ratio [HR], 1.52; 95{\%} confidence interval [CI], 1.40-1.65; P<0.001) and specifically of nonfatal ischemic stroke (adjusted HR, 3.06; 95{\%} CI, 2.62-3.57; P<0.001) and nonfatal hemorrhagic stroke rates (adjusted HR, 1.76; 95{\%} CI, 1.00-3.08; P=0.05). Excess risk for nonfatal hemorrhagic stroke appeared confined to the 1st year after a stroke/TIA (adjusted HR, 3.03; 95{\%} CI, 1.51-6.08 for the first year) and was particularly high in patients receiving dual antiplatelet therapy (adjusted HR, 5.21; 95{\%} CI, 1.24-21.90). Conclusions-In patients with coronary artery disease, a history of stroke/TIA is associated with an independent increase in risk of death, myocardial infarction, or stroke, including both ischemic and hemorrhagic stroke (the latter being smaller in absolute terms). This excess risk of hemorrhagic stroke is particularly high in patients receiving dual antiplatelet therapy and in the 1st year after stroke/TIA. This observation is important for selection of antithrombotic therapy in these patients. (Circulation. 2013;127:730-738.).",
keywords = "Antiplatelet agents, Hemorrhage, Myocardial ischemia, Stroke",
author = "Gregory Ducrocq and Pierre Amarenco and Julien Labreuche and Alberts, {Mark J.} and Mas, {Jean Louis} and Ohman, {E. Magnus} and Shinya Goto and Philippa Lavall{\'e}e and Bhatt, {Deepak L.} and Steg, {Ph Gabriel}",
year = "2013",
month = "2",
day = "12",
doi = "10.1161/CIRCULATIONAHA.112.141572",
language = "English (US)",
volume = "127",
pages = "730--738",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - A history of stroke/transient ischemic attack indicates high risks of cardiovascular event and hemorrhagic stroke in patients with coronary artery disease

AU - Ducrocq, Gregory

AU - Amarenco, Pierre

AU - Labreuche, Julien

AU - Alberts, Mark J.

AU - Mas, Jean Louis

AU - Ohman, E. Magnus

AU - Goto, Shinya

AU - Lavallée, Philippa

AU - Bhatt, Deepak L.

AU - Steg, Ph Gabriel

PY - 2013/2/12

Y1 - 2013/2/12

N2 - Background-Randomized trials of antithrombotics in coronary artery disease have identified previous stroke/transient ischemic attack (TIA) as a marker of increased intracranial bleeding risk. We aimed to further characterize the risk of ischemic and bleeding events associated with a history of stroke/TIA in patients with coronary artery disease. Methods and Results-From the international REduction of Atherothrombosis for Continued Health (REACH) registry of atherothrombosis, baseline characteristics and 4-year follow-up of 26 389 patients with coronary artery disease, including 4460 patients (16.9%) with a history of stroke/TIA, were analyzed. Patients with previous stroke/TIA had a higher rate of recurrent cardiovascular events (cardiovascular death, myocardial infarction, or stroke) than patients without (adjusted hazard ratio [HR], 1.52; 95% confidence interval [CI], 1.40-1.65; P<0.001) and specifically of nonfatal ischemic stroke (adjusted HR, 3.06; 95% CI, 2.62-3.57; P<0.001) and nonfatal hemorrhagic stroke rates (adjusted HR, 1.76; 95% CI, 1.00-3.08; P=0.05). Excess risk for nonfatal hemorrhagic stroke appeared confined to the 1st year after a stroke/TIA (adjusted HR, 3.03; 95% CI, 1.51-6.08 for the first year) and was particularly high in patients receiving dual antiplatelet therapy (adjusted HR, 5.21; 95% CI, 1.24-21.90). Conclusions-In patients with coronary artery disease, a history of stroke/TIA is associated with an independent increase in risk of death, myocardial infarction, or stroke, including both ischemic and hemorrhagic stroke (the latter being smaller in absolute terms). This excess risk of hemorrhagic stroke is particularly high in patients receiving dual antiplatelet therapy and in the 1st year after stroke/TIA. This observation is important for selection of antithrombotic therapy in these patients. (Circulation. 2013;127:730-738.).

AB - Background-Randomized trials of antithrombotics in coronary artery disease have identified previous stroke/transient ischemic attack (TIA) as a marker of increased intracranial bleeding risk. We aimed to further characterize the risk of ischemic and bleeding events associated with a history of stroke/TIA in patients with coronary artery disease. Methods and Results-From the international REduction of Atherothrombosis for Continued Health (REACH) registry of atherothrombosis, baseline characteristics and 4-year follow-up of 26 389 patients with coronary artery disease, including 4460 patients (16.9%) with a history of stroke/TIA, were analyzed. Patients with previous stroke/TIA had a higher rate of recurrent cardiovascular events (cardiovascular death, myocardial infarction, or stroke) than patients without (adjusted hazard ratio [HR], 1.52; 95% confidence interval [CI], 1.40-1.65; P<0.001) and specifically of nonfatal ischemic stroke (adjusted HR, 3.06; 95% CI, 2.62-3.57; P<0.001) and nonfatal hemorrhagic stroke rates (adjusted HR, 1.76; 95% CI, 1.00-3.08; P=0.05). Excess risk for nonfatal hemorrhagic stroke appeared confined to the 1st year after a stroke/TIA (adjusted HR, 3.03; 95% CI, 1.51-6.08 for the first year) and was particularly high in patients receiving dual antiplatelet therapy (adjusted HR, 5.21; 95% CI, 1.24-21.90). Conclusions-In patients with coronary artery disease, a history of stroke/TIA is associated with an independent increase in risk of death, myocardial infarction, or stroke, including both ischemic and hemorrhagic stroke (the latter being smaller in absolute terms). This excess risk of hemorrhagic stroke is particularly high in patients receiving dual antiplatelet therapy and in the 1st year after stroke/TIA. This observation is important for selection of antithrombotic therapy in these patients. (Circulation. 2013;127:730-738.).

KW - Antiplatelet agents

KW - Hemorrhage

KW - Myocardial ischemia

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=84873985510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873985510&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.112.141572

DO - 10.1161/CIRCULATIONAHA.112.141572

M3 - Article

C2 - 23277306

AN - SCOPUS:84873985510

VL - 127

SP - 730

EP - 738

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 6

ER -